Using epigenetic modifiers to treat retinal degeneration
Official title: Epigenetic Modifiers to treat Photoreceptor Degenerations
Funded at Skyran Biologics, INC. · NIH-10693776 · Data updated 2026-11-12
This study is exploring new eye treatments for people with Retinitis Pigmentosa that could help protect vision by using special drugs applied directly to the eye, aiming to improve how well you see and how well you can distinguish between different shades.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Skyran Biologics, INC. NIH-funded |
| Lab location | 1 site (Harrisburg, UNITED STATES) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $149,664 |
| NIH project number | 1R41EY035180-01 |
| Project ID | NIH-10693776 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with retinal degenerative diseases, such as Retinitis Pigmentosa.
✕Less likely to help
Patients with retinal conditions not related to degeneration or those with advanced stages of retinal disease may not benefit from this research.
What this research studies
This research focuses on developing topical treatments to combat retinal degenerative diseases, particularly Retinitis Pigmentosa. The approach involves using epigenetic modifiers that can reverse chromatin condensation, allowing photoreceptors to survive disease stresses. The researchers aim to deliver these drugs directly to the eye to minimize systemic side effects while preserving normal cell function. The study also investigates the effectiveness of these treatments in improving visual acuity and contrast sensitivity.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for patients suffering from retinal degenerative diseases, potentially improving their vision and quality of life.
How similar studies have gone: Previous research has shown promise in using epigenetic modifiers for similar conditions, indicating potential for success in this innovative approach.
Where this research is happening
-
Skyran Biologics, INC.
Harrisburg, United States Active
Researchers
- Principal investigator: Tombran-Tink, Joyce — Skyran Biologics, INC.
- Study coordinator: Tombran-Tink, Joyce
Related research
Other NIH-funded projects on the same topics.
-
A new treatment for vision loss caused by diabetes
This study is working on a new eye treatment for people with diabetes to help protect their vision from diabetic retinopathy, using a special protein that has shown promise in reducing inflammation and improving eyesight in tests.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.